July 24, 2025 AlzeCure’s rights issue oversubscribed and the company resolves on a directed share issue under the framework of an overallotment option
July 16, 2025 AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue
July 2, 2025 The extraordinary general meeting of AlzeCure Pharma AB approved the decision on the new issue of shares
June 17, 2025 AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the upcoming Rights Issue
July 18, 2024 AlzeCure Pharma carries out a directed share issue in follow-up to a previously given subscription commitment
May 24, 2023 AlzeCure announces positive Phase IIa clinical study data in neuropathic pain with the non-opioid ACD440
December 21, 2022 Preliminary outcome in AlzeCure Pharma’s rights issue – Oversubscribed to 128 percent
June 29, 2022 Positive data from the clinical phase I MAD study with AlzeCure’s Alzheimer’s project NeuroRestore ACD856
April 13, 2022 AlzeCure’s rights issue is registered and the trading in Paid Subscription Shares ceases
April 11, 2022 AlzeCure carries out a set-off issue in connection with ACD440 entering phase II and Acturum Life investing in the company
November 12, 2020 AlzeCure receives approval to start clinical Phase I trial with ACD856 in Alzheimer’s disease
November 11, 2020 Poster presentation with the Alzstatin platform now available on AlzeCure’s website
October 13, 2020 AlzeCure gets abstract on the NeuroRestore platform against Alzheimer’s accepted for poster presentation at CTAD
October 8, 2020 AlzeCure gets abstract on the Alzstatin platform against Alzheimer’s accepted for poster presentation at CTAD
April 30, 2020 A new doctoral thesis in Alzheimer’s presented today by AlzeCure Pharma and Karolinska Institutet
April 2, 2020 AlzeCure Pharma today presented key preclinical data on its novel cognitive enhancer at the AAT-AD/PD conference
March 16, 2020 AlzeCure Pharma to present late breaking abstract at the AAT-AD/PD conference (Advances in Alzheimer’s and Parkinson’s Therapies)
March 3, 2020 An van Es-Johansson joins management team at AlzeCure Pharma – resigns from Board of Directors
January 7, 2020 AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain
May 3, 2019 AlzeCure changes direction for its drug candidate ACD855 within the NeuroRestore platform
